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Fueled by concerns over antimicrobial resistance and heightened emphasis on optimizing antimicrobial use, stewardship
programs have populated facilities for over a decade [1, 2].
Regulatory agencies including the Joint Commission (TJC)
and the Centers for Disease Control and Prevention (CDC)
have provided blueprints for antimicrobial stewardship programs (ASPs), which serve as guidelines for institutions
certified by TJC [3, 4]. Stewardship expansion across the continuum of care is vital to curbing antimicrobial resistance.
Successful ASPs are interprofessional, including infectious
diseases (ID) pharmacists, physicians, and microbiologists
collaborating with stewardship extenders or non-ID-trained
specialists [1, 5].
To achieve stewardship goals, ASPs must maintain knowledge of evidence-based ASP interventions and newly approved
antimicrobials [6]. From 2016 to 2017, there were 40% and
46% increases in peer-reviewed publications using the search
terms “antibiotic stewardship” and “antimicrobial stewardship,”
respectively (Medline searches, accessed September 7, 2018),
with noted growth in international stewardship and rapid
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diagnostic technology (RDTs) scholarship [7–9]. Members
of the Southeastern Research Group Endeavor (SERGE-45)
systematically compiled the top peer-reviewed publications
from 2017 involving an ASP intervention. Table 1 provides a
brief review and commentary. A previous publication by these
authors, using similar criteria, reviewed top publications from
2016 [21]. We anticipate that this will be a key resource for ASPs
for both implementation strategies and to mentor learners on
key peer reviewed literature.
METHODS

Using a modified Delphi technique, members of the SERGE-45
network identified antimicrobial stewardship publications from
2017 considered to be significant [22]. SERGE-45 is a network
of infectious diseases practitioners, primarily pharmacists, who
are clinician-educators and scholars. Eligible articles met the
following inclusion criteria: (1) published in 2017, including
electronic, “early-release” publications, and (2) must include an
“actionable” intervention. Guideline manuscripts or those without an actionable intervention were excluded.
All coauthors nominated publications from 2017 and provided comments via a REDCap Survey [23]. A PubMed search
using “antimicrobial stewardship” for the time period of 2017
revealed 934 potential publications. DBC and PBB screened
abstracts to ensure that all relevant articles were considered.
Three manuscripts were added to the original list from the
survey results. The included articles were distributed to the
SERGE-45 network for individual ranking based on contribution and/or application to ASP. A web-based teleconference
with the co-authors established consensus on the top 13 articles (Table 1) described herein.
Top Stewardship Intervention Papers in 2017 • ofid • 1
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With an increasing number of antimicrobial stewardship–related articles published each year, attempting to stay current is challenging. The Southeastern Research Group Endeavor (SERGE-45) identified antimicrobial stewardship-related peer-reviewed literature
that detailed an “actionable” intervention for 2017. The top 13 publications were selected using a modified Delphi technique. These
manuscripts were reviewed to highlight the “actionable” intervention used by antimicrobial stewardship programs to provide key
stewardship literature for training and teaching and identify potential intervention opportunities within their institutions.
Keywords. antibiotics; antimicrobial stewardship; infectious diseases; intervention.

Table 1.
Study
Citation
Wenzler
et al.
2017
[10]

Summary of Included Studies

Study Design

Intervention Summary

Primary and Key Secondary Outcomes

Implementation of scoring tool and subsequent
prepopulated progress note embedded with EMR
triggered by positive results of Verigene
gram-positive blood culture assay. Adherence
to quality components (primary) and associated
clinical outcomes were assessed.

Improved adherence to quality-of-care components
• Pre-intervention: 68.9% vs postintervention: 92.3%; P = .008
Increased proportion of ID consults obtained
• Pre-intervention: 75.6% vs postintervention: 94.9%; P = .015
Increased timeliness of initiation of targeted therapy
• Pre-intervention: 91.8 hours vs postintervention: 54.3 hours; P = .079

Smith et Retrospective,
al. 2017
single-center
[11]
study

ASP education provided prestudy on the clinical
utility of the MRSA nasal PCR to predict the involvement of MRSA in nosocomial pneumonia.
ASP provided recommendations to discontinue antiMRSA therapy based on the PCR screening.

Diagnostic performance of the MRSA nasal PCR panel for detecting
MRSA pneumonia
Respiratory culture (n = 400):
• NPV: 99.03%
• PPV: 37.36%
• Sensitivity: 91.89%
• Specificity: 84.3%
Respiratory culture (n = 164):
• NPV: 96.83%
• Median 7.4 days from PCR to time to culture
Respiratory culture (n = 68):
• NPV: 100%
• Median 13.4 days from PCR to time to culture
Respiratory culture (n = 23):
• NPV: 87.5%
• Median 21.9 days from PCR to time to culture
Vancomycin de-escalation
• 45.3% (n = 169) with negative PCR result (n = 309)
• No difference in AKI
• Cost reductions in laboratory monitoring and medication

Mullin et QuasiFirst intervention, implemented in 2013: optimizing
al. 2017
experimental
Foley catheter insertion, maintenance, and re[12]
study with an
moval with periodic audits in ICUs.
initial interven- Second intervention, implemented in 2014: adopting
tion, followed by the ACCCM/IDSA recommendations for evaluating
an observation
new fever in critically ill patients, which emphaphase, followed sized that urine cultures should only be evaluated
by another
in patients at high risk of invasive infections.
intervention,
Interventions targeted a reduction in NHSNfollowed by
reported CAUTI and HABSI.
another observation phase

Reduction in the rate of CAUTIs per 1000 catheter-days
• 3.0 in 2013 vs 1.9 in 2014: RR, 0.6291; 95% CI, 0.49–0.81;
P = .0003 Nonsignificant reduction in the rate of HABSIs per 1000
patient-days
• 2.8 in 2013 vs 2.4 in 2014; P = .15
Nonsignificant reduction in the rate of HABSIs secondary to
Enterobacteriaceae per 1000 patient-days
• 0.71 in 2013 to 0.66 in 2014: RR, 1.1; 95% CI, 0.73–1.60; P = .72

Shea et
Multicenter, qua- Following development of a health care system–
al. 2017
si-experimental
wide respiratory fluoroquinolone restriction policy,
[13]
study
the impact of the following interventions was
measured at 4 adult hospitals:
1.Educational campaigns, including pharmacist competency and prescriber presentations and emails
delivered over a 3-month period.
2.Prospective audit and feedback on respiratory fluoroquinolone orders performed by pharmacists.

Reduction in fluoroquinolone utilization (DOT/1000 PD)
• Pre: 41.0 vs education: 21.5; P = .023; vs postrestriction: 4.8;
P < .001
Reduction in CDI cases/10 000 PD
• Pre: 4.0 vs education: 3.43 (P = .044) vs postrestriction: 2.2;
P = .044
Increased appropriate use of a respiratory fluoroquinolone in patients
receiving 1 or more doses
• Pre: 74/232 (32%) vs postrestriction: 74/130 (57%); P < .001
Increased appropriate use of a respiratory fluoroquinolone in
patients receiving 2 or more doses
• Pre: 67/191 (35%) vs postrestriction: 47/65 (72%); P < .001
Decline in moxifloxacin annual acquisition cost
• Pre: $123 273 vs postrestriction: $12 273; P < .002

Broyles et Singe-center,
al. 2017
retrospective
[5]
pre- and
postintervention
study

Introduction of a pharmacist-driven PCT algorithm,
allowing pharmacists to order PCT and recommend antibiotic changes.
Patients were included based on DRGs for sepsis,
COPD, pneumonia, and respiratory infections.
Pharmacists could order PCT and could encourage
or discourage antibiotic usage based on PCT
changes, in accordance with PCT algorithm.

Decrease in median antibiotic DOT
• Pre-intervention: 17 (IQR, 8.5–22.5) vs postintervention: 9 (IQR,
6.5–12); P < .001
Decline in hospital mortality
• Pre-intervention: 7.6% vs postintervention: 2.9%; P < .001
Decrease in 30-day readmissions
• Pre-intervention: 22.4% vs postintervention: 11.1%; P < .001
Decrease in antibiotic-associated ADEs
• Pre-intervention: 16.2% vs postintervention: 8.1%; P < .001
Decrease in CDI incidence
• Pre-intervention: 2.5% vs postintervention: 0.9%; P < .001

Eljaaly et Retrospective,
al. 2018
single-center,
[14]
pre- and
postintervention
study

Additional authorization of restricted antibiotics required on day 3 of treatment. ASP team provided
feedback directly to ordering provider if agent was
considered suboptimal. Changes in antibiotic DOT
and associated clinical outcomes (LOS and hospital mortality) were assessed.

Decrease in overall restricted antibiotic median DOT
• Pre-intervention: 5 vs postintervention: 4; P < .001
Reduced LOS
• Pre-intervention: 8 days vs postintervention: 6 days; P < .001
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Retrospective,
single-center
quasi-experimental

Table 1.
Study
Citation

Continued

Study Design

Intervention Summary

Primary and Key Secondary Outcomes

Dissemination of institutional guidelines detailing
the selection and duration of oral step-down antibiotic recommendations at discharge, coupled
with prospective audit and feedback of discharge
prescriptions by pharmacists.

Nonsignificant reduction in antibiotic median total DOT
• Pre-intervention: 10 (IQR, 7–13) days vs postintervention: 9 (IQR,
6–13) days; P = .13
Reduced antibiotic median DOT prescribed at discharge
• Pre-intervention: 6 (IQR, 4–10) days vs postintervention: 5 (IQR, 3–7)
days; P = .003
Reduced antibiotic median inpatient DOT
• Pre-intervention period: 3 (IQR, 3–5) days vs postintervention: 4
(IQR, 3–5) days; P = .01
Decreased use of antibiotics with broad activity against gram-negative
bacteria
• Pre-intervention period: 51% vs postintervention: 40%; P = .02
No significant differences in treatment failure, readmission, CDI, or
adverse events

Bookstaver Quasiet al.
experimental
2017 [8]
cohort study

Implementation of an antimicrobial stewardship
bundle for GNBSIs:
1) GNBSI management institutional guidelines.
2) Prospective audit and feedback on all positive
blood cultures.
3) Sequential introduction of 2 RDTs, MALDI-TOF
and FilmArray BCID panel.

Improved appropriateness of empirical therapy improved overall
• Pre-intervention: 91% vs postintervention: 95%; P = .02
Improved appropriateness of empirical therapy in patients with BSI
due to P. aeruginosa/chromosomally mediated AmpC-producing
Enterobacteriaceae
• Pre-intervention: 87% vs postintervention: 97%; P = .02
Improved appropriateness of empirical therapy in critically ill with a Pitt
bacteremia score of ≥4
• Pre-intervention: 89% vs postintervention: 97%; P = 0.06
Improved time to de-escalation from combination antimicrobial therapy
• Overall, pre-intervention: 2.8 days vs postintervention: 1.5 days; P
< .001
• APBLs, pre-intervention: 4.0 days vs postintervention: 2.5 days; P
< .001
• Carbapenems, pre-intervention: 4.0 days vs postintervention: 2.5
days; P < .001
• Two-thirds of all de-escalation occurred before return of susceptibilities in the postintervention period

Leis et al.
2017
[16]

ASP pharmacists and physicians were trained to
perform and interpret BLAST in collaboration with
allergy specialists. A structured allergy history,
followed by pharmacist-performed BLAST when
needed, was implemented for patients with
reported β-lactam allergies who needed β-lactam
therapy.

Increased utilization of preferred β-lactam therapy in patients with
reported β-lactam allergies
• Baseline: n = 124/246 (50%) vs intervention period: n = 313/386
(81%)
• No reported increase in adverse effects
• The intervention required an average of 1 hour of pharmacist time
per patient

Audit with real-time feedback of adult inpatients
based on findings from microbiologic samples and
chest imaging.

Decrease in mean antibiotic DOT
• Pre-intervention: 4.1 days vs postintervention: 2.8 days; 95% CI,
0.3–2.3; P < .01

Multicenter,
prospective
evaluation

Lowe et
Quasial. 2017
experimental
[17]
pre- and postintervention
study

Dumkow et Retrospective, de- Three pharmacists (ID pharmacist, ED pharmacist,
al. 2017
scriptive study
and pharmacy resident) located off campus from
[18]
an urgent care center affiliated with main hospital
reviewed positive cultures and intervened when
required under a CPA over the course of a calendar year.

Follow-up intervention was required in 320 of 1461 (22%) isolates
• The most common cultures requiring intervention were urine
(25%) and STIs (25%), requiring approximately 15 minutes per
intervention
• Most patients did not require a new/changed antimicrobial prescription upon follow-up for 2 primary reasons: Sexually transmitted
infection cultures had been treated appropriate (only notification
of results required) or patients were asymptomatic upon follow-up
(unique to center’s CPA)
• The average time for all aspects of intervention including documentation was 15 minutes
Treatment outcomes of these interventions were not evaluated

Rac et al.
2018
[19]

No difference in time to adequate therapy in business hours
population
• Pre-intervention: 2h 57min vs postintervention: 2h 15min; P = .094
Decrease in time to adequate therapy in total population
• Pre-intervention: 3h 30min vs postintervention: 2h 9min; P = .021
Decrease in time to adequate therapy order in total population
• Pre-intervention: 1h 35min vs postintervention: 24min; P = .017
Increase proportion of ID consults obtained
• Pre-intervention: 36% vs postintervention: 75%; P < .001
Increase in proportion of ophthalmology consults obtained
• Pre-intervention: 35% vs postintervention: 69%; P < .001
Increase in streamlining of IV to PO antifungals
• Pre-intervention: 18% vs postintervention: 39%; P = .015

Single-center,
quasi-experimental, preand postintervention
study

Antifungal susceptibility testing and real-time
culture alerts, leading to a single phone call from
the ASP pharmacist to the primary team with
recommendations for antifungal therapy and other
candidemia management strategies (infectious
diseases consult, remove lines, ophthalmology
examination, repeated blood cultures).
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Yogo et
Quasial. 2017
experimental
[15]
retrospective
study

Table 1.

Continued

Study
Citation

Study Design

Wilson et Pre- and postal. 2017
intervention
[20]
surveys

Intervention Summary

Primary and Key Secondary Outcomes

A free 6-module online course was made available
to nurses. Pre-/postintervention surveys assessed
demographics, perceptions, and knowledge.

Increase in nursing knowledge scores
• Precourse: 75% vs postcourse: 86%; P < .001
Nurses had increased agreement that their role influences whether
long-term care residents receive antibiotics (P < .001)

Abbreviations: ACCCM, American College of Critical Care Medicine; ADE, adverse drug event; AKI, acute kidney injury; APBLs, antipseudomonal β-lactams; ASP, antimicrobial stewardship
program; BCID, blood culture identification; BLAST, β-lactam allergy skin testing; CAUTIs, catheter-associated urinary tract infections; CDI, Clostridioides difficile infection; CI, confidence
interval; COPD, chronic obstructive pulmonary disease; CPA, collaborative practice agreement; DOT, days of therapy; DRG, diagnosis-related groups; ED, emergency department; EMR, electronic medical record; GNBSIs; gram-negative bloodstream infections; HABSIs, hospital-acquired bloodstream infections; ICUs, intensive care units; ID, infectious diseases; IDSA, Infectious
Diseases Society of America; IQR, interquartile range; IV, intravenous; LOS, length of stay; MALDI-TOF, matrix assisted laser desorption ionization-time of flight mass spectrometry; MRSA,
methicillin resistant Staphylococcus aureus; NHSN, National Healthcare Safety Network; NPV, negative predictive value; PCR, polymerase chain reaction; PCT, procalcitonin; PD, patientdays; PO, oral; PPV, positive predictive value; RDT, rapid diagnostic technology; RR, rate ratio; STIs, sexually transmitted infections.

Health Informatics and Staphylococcus aureus Bacteremia

The correlation between infectious diseases consultation and
improved patient outcomes in Staphylococcus aureus bacteremia (SAB) has been well described [24]. The use of health
informatics (HI), including electronic medical records (EMRs)
and clinical decision support software, has the potential to augment patient care in institutions with limited ID and/or ASP
resources.
Wenzler and colleagues conducted a retrospective quasi-experimental study of hospitalized patients with SAB [10].
Patients who were incarcerated, who received an ID consult
before identification of SAB, or who were transferred from
an outside hospital or discharged against medical advice were
excluded. The objective was to evaluate the impact of incorporating HI into SAB management via a pharmacist-driven
initiative. The primary outcome was overall compliance with
quality-of-care components, which consisted of ID consult,
repeat blood cultures, echocardiogram, and initiation of SABtargeted therapy. Secondary outcomes included time to pharmacist intervention, duration of bacteremia, length of hospital
stay (LOS), infection-related LOS, 30-day readmission, and
30-day mortality. The study used a 3-month pre- and postintervention study design.
Of 123 patients screened, 84 patients were included. Most
patients were excluded due to ID consult before SAB. Over half
of the isolates displayed methicillin resistance. In the postintervention arm, targeted treatment was initiated significantly more
often (100% vs 84%; P = .013), at a median of 40 hours sooner.
The incidence of ID consult increased significantly, by approximately 20%. All-cause mortality was lower in the postintervention arm (15.6% vs 2.6%; P = .063), although this difference was
not statistically significant.
The findings of this study are limited by the small sample size
and retrospective study design in a single center, as well as the
use of RDT, as not all centers may have access. However, utilization of HI, development of institutional guidelines for management of SAB, and intervention by non-ID pharmacists should
be broadly applicable to optimizing patient care.
4 • ofid • Chastain et al

Utility of MRSA Nasal PCR Assays in ICU Patients With Nosocomial
Pneumonia

The American Thoracic Society and Infectious Diseases Society
of America (IDSA) nosocomial pneumonia guidelines recommend empiric methicillin-resistant S. aureus (MRSA) coverage in at-risk patients; however, no guidance is provided for
de-escalation of therapy before respiratory culture results [25].
Consequently, empiric anti-MRSA therapy is continued, contributing to antimicrobial overuse. MRSA nasal polymerase
chain reaction (PCR) assays demonstrate high negative predictive values (NPVs) in ruling out MRSA as the causative pneumonia pathogen and supporting de-escalation of therapy before
or in absence of culture results [26].
Smith and colleagues evaluated the clinical utility and diagnostic performance of the rapid MRSA nasal PCR assay in adult
intensive care unit (ICU) patients with nosocomial pneumonia [11]. Eligible patients underwent MRSA nasal PCR assay
screening before or within 48 hours of ICU admission, and an
initial respiratory culture was collected within 7 days of screening. Before the study, the ASP team educated ICU prescribers
about the utility of the assay for anti-MRSA therapy de-escalation, and during the study period, they provided de-escalation
recommendations based on screening results. Changes in NPV
over time, acute kidney injury (AKI) incidence, and medication
and laboratory cost avoidance were evaluated.
The prevalence of culture-confirmed MRSA pneumonia was
9.3%. The diagnostic performance of the assay for detecting
MRSA pneumonia from initial culture was as follows: NPV,
99.03%; positive predictive value (PPV), 37.36%; sensitivity,
91.89%; specificity, 84.3%. Vancomycin de-escalation occurred
in 45.3% of patients with a negative PCR. Early vancomycin
discontinuation yielded medication and laboratory cost avoidances but did not impact the AKI rate.
This analysis reinforces the high NPV of MRSA nasal PCR
assay for predicting MRSA as the causative pathogen in nosocomial pneumonia. The external validity of this study is limited, as
use of the assay was pre-established, pneumonia diagnosis was
based on EMR documentation, MRSA pneumonia prevalence
was low, and the ASP team performed rounds daily to provide
de-escalation recommendations.

Downloaded from https://academic.oup.com/ofid/article/6/4/ofz133/5419869 by guest on 25 May 2022

RESULTS

Reducing ICU CAUTIs

Respiratory Fluoroquinolone Restriction Program

Fluoroquinolones are among the most commonly prescribed
antibiotics in the United States [13]. In addition to increased
rates of resistance and significant adverse drug events (ADEs),
fluoroquinolones adversely impact CDI rates.
In a multicenter, quasi-experimental design, Shea and colleagues evaluated 4 hospitals restriction of moxifloxacin, their
formulary respiratory fluoroquinolone [13]. Pre-approved criteria for use included ID consultation or approval; endophthalmitis or ophthalmic surgery; or community-acquired pneumonia
(CAP) or severe acute exacerbation of chronic obstructive pulmonary disease (COPD) plus 1 of the following: severe β-lactam allergy, receipt of a cephalosporin in the prior 3 months, or
culture-proven ceftriaxone-resistant or penicillin-intermediate

or -resistant Streptococcus pneumoniae. Pharmacists performed
prospective audit and feedback (PAF) of moxifloxacin orders
when criteria for use were not met. Educational interventions
included implementing a pharmacist-driven β-lactam allergy
assessment tool, presentations to clinicians conducted by ID
pharmacists, and emails to key stakeholders.
Outcomes of interest included monthly use (DOT/1000
PD) of moxifloxacin for 5 months pre-intervention, during a
3-month education period, and for 12 months postintervention;
moxifloxacin acquisition costs; usage of other antimicrobials
that could influence CDI rates; and appropriateness of moxifloxacin prescriptions. In segmented regression analysis, each
hospital achieved average reductions of 48% to 88% in moxifloxacin usage P < .001. Usage rates of other key antimicrobial
agents were unaffected. CDI rates decreased by approximately
50% from baseline (P = .044).
The strengths of this intervention were its multicenter design,
measurement of off-target antimicrobials, and evaluation of
appropriateness during pre- and postintervention periods. The
authors noted major reductions in usage, and CDI rates were
achieved despite maximal “appropriate use” rates of approximately 70% in the first 6 months of the intervention. ASPs
interested in implementing a similar strategy must consider the
resources necessary to build consensus around specific criteria,
staffing to perform PAF, and decision support to increase adoption of the criteria.
Impact of Procalcitonin on Antibiotic Exposure

Procalcitonin (PCT), a biomarker produced in response to
bacterial infections, is Food and Drug Administration (FDA)
approved for use in and respiratory infections and is increasingly used by ASPs to impact antibiotic consumption [29].
Broyles performed a single-center, pre–post, retrospective
cohort study to assess the impact of a local pharmacist-driven
PCT algorithm (PCT-A) [5]. Outcomes included median antibiotic DOT, in-hospital mortality, 30-day readmission, CDI,
and ADE. This study compared 4 years before (2006–2009)
and 4 years after (2011–2014), with the PCT implementation
year (2010) as a washout period. Patients who received nonprophylactic intravenous (IV) antibiotics were included based on
diagnosis-related groups (DRGs). ASP workflow before PCT-A
included patient review for antibiotic use. After introduction of
PCT-A, PCT could be ordered and used to recommend antibiotic changes to clinicians as indicated in the algorithm.
There were 985 pre-PCT-A patients and 1167 post-PCT-A
patients included. The groups were comparable, except the postcohort had more patients with sepsis (1.3% vs 7.7%; P < .001)
and COPD (16.9% vs 18.8%; P < .001) and fewer with pneumonia (59.8% vs 54.9%; P = .02). There was a 47% reduction
in median DOT in the post-PCT-A cohort (P < .001). Hospital
mortality (P < .001), 30-day readmission (P < .001), antibiotic ADE (P < .001), and CDI (P = .002) were all lower in the
Top Stewardship Intervention Papers in 2017 • ofid • 5
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Catheter-associated urinary tract infections (CAUTIs) represent approximately 75% of all hospital-acquired UTIs [27]. Risk
factors include duration of catheterization, female sex, older
age, and failure to maintain a closed drainage system. Treatment
of CAUTIs involves administration of antibiotics and catheter
removal when possible [28]. However, asymptomatic bacteriuria (ASB) associated with indwelling urinary catheters is
not diagnostic of CAUTIs and should not be treated in most
patients [27, 28].
Mullin and colleagues report a multifaceted multidisciplinary
approach to reducing the incidence of CAUTIs in adult and
pediatric ICUs [12]. In 2013, they implemented interventions
targeted at optimizing Foley catheter use. In 2014, they adopted
best-practice recommendations for evaluating new fever in critically ill patients. Throughout 2013 and 2014, results of CAUTIs
and hospital-acquired bloodstream infections (HABSIs) surveillance were recorded prospectively, and device utilization ratios
(DURs) and rates of CAUTIs and HABSIs were calculated. The
primary outcome was the rate of CAUTIs. Between 2013 and
2014, the number of ICU patient-days (PDs) and DURs were
comparable (74 705 vs 75 569 and 0.7 vs 0.68, respectively),
whereas the number of urine cultures decreased from 4749 to
2479. The rate of CAUTIs per 1000 catheter-days was significantly reduced. Reductions in the rates of HABSIs and HABSIs
secondary to Enterobacteriaceae were also observed.
This study’s multifaceted approach focusing on the appropriate use of Foley catheters and the “stewardship of culturing”
successfully reduced the rate of CAUTIs by 33%, along with a
reduction in overall rates of HABSIs or HABSIs secondary to
Enterobacteriaceae. The authors report aggregate data rather
than patient-specific data and did not report antibiotic days of
therapy (DOT), resistance rates, Clostridioides difficile infection
(CDI) rates, LOS, or resource utilization. In addition, the analysis suffered from a lack of interrupted time-series analysis, did
not report the extent of adherence to the interventions, and did
not have a control group.

post-PCT-A cohort. Pharmacist recommendations were highly
accepted (95%) by the end of the study period.
The addition of a pharmacist-driven PCT-A impacted antibiotic consumption and patient outcomes at a small, rural
hospital. Limitations include the applicability to larger health
care settings with a higher pharmacist-to-patient ratio. The
DOT calculation example provided in the paper used a halfDOT, which is not consistent with the current CDC–National
Healthcare Safety Network guidelines [30]. Other limitations
acknowledged by the author include LOS variations, lack of protocol adherence capture, and physician staffing model changes
in 2012, which may have influenced the results.

Antimicrobial preauthorization (PA) and PAF are considered
critical support elements of ASPs, and inclusion of 1 or both
is recommended by current guidelines [29]. Both interventions are associated with reductions in overall antimicrobial
use, resistance, and CDI rates. However, recent studies suggest
a more rapid benefit with PA, at the risk of sacrificing the sustained effects of PAF correlated with relationship-building and
direct provision of education [29].
Eljaaly and colleagues retrospectively examined the effect of
combining both PA and PAF via prescription reauthorization on
appropriate use of intravenous acyclovir, aztreonam, cefepime,
ciprofloxacin, daptomycin, ertapenem, fluconazole, linezolid,
voriconazole, meropenem, micafungin, piperacillin/tazobactam, oral vancomycin, fluconazole, linezolid, and voriconazole
[14]. The ASP team re-reviewed restricted antimicrobial orders
on day 3, and if considered suboptimal, the ASP team discussed
the case directly with the ordering provider. Outcomes included
restricted antimicrobial DOT per patient and per agent, hospital LOS, in-hospital mortality, and proportion of patients on
antimicrobial therapy for >4 days before and after implementation of the required reauthorization. Statistically significant
decreases in all end points except in-hospital mortality were
observed.
The authors note that required reauthorization at day 3
allows for incorporation of culture and clinical data into assessment of antimicrobial appropriateness and facilitates additional
discussion of de-escalation, IV to oral (PO) conversion, and
duration of therapy. Limitations of the study include assessment
of only restricted antimicrobial agents, not overall use, and the
pre–post study design. Further research is needed to assess the
sustainability of the intervention, long-term impact, ability to
expand beyond restricted antimicrobials, and provider satisfaction with the process.
Reducing Prescription of Broad-Spectrum Antibiotics and Treatment
Duration at Hospital Discharge

Antimicrobial use at hospital discharge is often overlooked,
although up to 70% of treatment durations are completed in the
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Early Streamlining (Without Susceptibilities) Possible in Gram-Negative
BSIs Using RDT and ASP Bundle

RDT, specifically used in bloodstream infections (BSIs), shortens time to organism identification, leading to earlier appropriate therapy [9]. Several ASPs use RDT for de-escalation
purposes, although this is primarily demonstrated with vancomycin [34]. Few data exist exploring the impact of RDTs, specifically using multiple RDTs, on early de-escalation in GN BSIs,
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outpatient setting [31]. Few published studies discuss interventions that reduce the duration and use of broad-spectrum antibiotics postdischarge [32, 33].
Yogo and colleagues evaluated syndrome-specific antibiotic
therapy prescribed at discharge [15]. The intervention comprised 2 parts: (1) dissemination of institutional guidelines via
laminated pocket-size cards, intranet resources, and a smartphone app on de-escalating to PO antibiotics for CAP, UTIs,
skin and soft tissue infections (SSTIs), health care–associated
pneumonia (HCAP), nosocomial pneumonia HAP, COPD,
CDI, and Helicobacter pylori for an appropriate duration at discharge; and (2) PAF of discharge prescriptions by pharmacists.
Three hundred patients in the pre-intervention group were
compared with 200 in the postintervention group to determine the effect on DOTs, and number of patients receiving
broad-spectrum gram-negative (GN) antibiotics, fluoroquinolones, or amoxicillin/clavulanate at discharge.
UTIs, CAP, and SSTIs were the most common indications in
both groups, but COPD exacerbations occurred more often in
the postintervention group (18% vs 8%; P = .001), increasing
azithromycin use (12% vs 20%; P = .03). Approximately threefourths of patients had at least 1 culture obtained, whereas only
30% were positive in both groups. Escherichia coli, Streptococcus
spp., and S. aureus were isolated most commonly. Significantly
fewer patients in the postintervention group received
broad-spectrum GN antibiotics (P = .02), attributed to a reduction in fluoroquinolone use (38% vs 25%; P = .002). Total DOTs
were comparable between groups, whereas DOT postdischarge was significantly decreased postintervention (P = .003).
However, inpatient DOT was significantly higher during the
postintervention period (P = .01). Of the 40% of discharge prescriptions reviewed, pharmacists contacted prescribers with
recommendations in 27% of cases, with a 67% success rate. No
difference in treatment failure, readmission for the same indication, CDI, or ADEs was observed.
Development and dissemination of institutional syndrome-specific guidelines may assist providers with selecting
the appropriate antibiotic for an appropriate duration at discharge, a frequent shortcoming of inpatient ASP. Significant
improvements in selection of discharge antibiotics and treatment duration occurred despite few cases being reviewed by
pharmacists, which may allow an intervention of this nature to
be developed regardless of institutional limitations.

Point-of-Care β-Lactam Allergy Skin Testing by ASPs

The IDSA and Society for Healthcare Epidemiology of America
2016 antimicrobial stewardship guidelines recommend allergy
assessment and β-lactam allergy skin testing (BLAST) when
clinically appropriate [29]. However, many institutions lack the
dedicated allergy and immunology specialty services required
for inpatient drug allergy testing.
Leis and colleagues conducted a multicenter prospective
study evaluating implementation of ASP-run BLAST services
[16]. ASP pharmacists and at least 1 ID physician from each
hospital completed BLAST training with an allergist. The ASP
pharmacist conducted a structured allergy history and, to eligible patients, offered, performed, and interpreted BLAST. If
BLAST was negative, the β-lactam antibiotic was prescribed,
the EMR was updated, and patients received a letter explaining the BLAST results. Outcomes included the proportion of
patients receiving preferred β-lactam therapy, ADEs, hospital
LOS, and 30-day readmission or death.

At baseline, 246 patients reported a β-lactam allergy and
had an infection where a β-lactam was the preferred therapy;
50% (124/246) received a β-lactam. In the intervention phase,
386 patients met criteria and 81% (313/386) received a β-lactam after structured allergy assessment and possible provision
of BLAST (P < .001). The odds of receiving preferred β-lactam
therapy were higher in the intervention period (odds ratio, 4.5;
95% CI, 2.4–8.2; P < .0001). No significant differences were
observed among the secondary outcomes, including ADEs.
Only 1 patient tested had a positive BLAST. The authors noted
that BLAST required up to 1 hour of pharmacist time at the
patient bedside.
This study demonstrates that ASPs can increase β-lactam utilization rates in patients reporting β-lactam allergies utilizing a
structured allergy assessment followed by pharmacist-administered BLAST. When considering the implementation of this
approach, the protocol should be institution-specific and developed in collaboration with allergy specialists. The ASP should
consider the pharmacist and physician time involved when allocating and requesting resources.
Improving Management of Hospitalized Patients With Viral Respiratory
Tract Infections

Often, patients presenting with respiratory tract infections
(RTIs) are started on empiric antibiotics because the infectious
etiology is unclear. Recent developments of real-time multiplex PCR testing allow for improved identification of causative
respiratory viruses, but implementation alone may not improve
unnecessary antibiotic therapy [36].
Lowe and colleagues performed a quasi-experimental pre-/
postintervention study to evaluate the impact of ASP recommendations on antibiotic DOT in patients admitted with viral RTIs
[17]. The intervention consisted of PAF and targeted patients
with a positive PCR result for influenza A or B, respiratory
syncytial virus, parainfluenza 1, 2, or 3, adenovirus, or human
metapneumovirus, obtained from upper or lower respiratory
tract samples. An ASP consultation was obtained in patients
with no positive bacterial cultures and absence of radiographic
findings. Similar numbers of patients were on antibiotics in
the both groups (pre-intervention: 70/92; vs postintervention:
98/118; P = .21). Integrating virologic PCR testing decreased
antibiotic DOT by a mean of 1.3 days (P < .01). ASP recommendations were accepted in 77% of cases postintervention. Among
patients with positive influenza PCR, oseltamivir was started
in significantly more patients in the postintervention group
(31/43 vs 21/22; P = .03). No difference in LOS, ICU admission,
receipt of mechanical ventilation within 14 days, restarting antibiotics within 14 days, CDI, or readmission within 30 days was
observed between groups.
Implementation of syndrome-specific RDT may limit unnecessary antibiotic use in hospitalized patients with viral RTIs.
Additionally, identification of influenza may lead to more
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where combinations of antipseudomonal β-lactams (APBLs)
are commonly employed.
Bookstaver and colleagues conducted a quasi-experimental
cohort study at 2 hospitals measuring the impact of ASP bundle
on both appropriate empirical therapy and time to de-escalation
[8]. The intervention included (1) a BSI guideline and treatment
algorithm, (2) stewardship team PAF for BSIs, (3) introduction
of MALDI-TOF for all positive blood cultures, and (4) subsequent introduction of FilmArray BCID. Outcomes were compared between pre- and postintervention periods, including 2
independent postintervention period phases (Phase 1: MALDITOF alone; Phase 2: MALDI-TOF plus FilmArray BCID).
Among 1163 unique patients (830 pre-intervention and 333
postintervention), a urinary source (53%) was the most common, and E. coli was most frequently isolated. The average time
to de-escalation was 2.5 days, approximately 1.5 days sooner
in the postintervention period, and was further reduced to
2.2 days in Phase 2 of the postintervention period. Appropriate
therapy within 48 hours of BSI improved from 91% to 95%
between periods, despite the significant reduction in APBL and
combination therapy. The greatest improvement was observed
in ICU patients with Pitt bacteremia scores ≥4 (97% post- vs
89% pre-intervention period). Nearly two-thirds of all de-escalation occurred before susceptibility reporting.
Although retrospective in nature, this study supports an
active ASP bundling of RDTs with local guidelines to reduce
antibiotic utilization and improve empirical therapy and time
to de-escalation. This stewardship group also utilizes prediction models in their guidelines, helping to facilitate early
de-escalation. Two additional takeaways related to these data:
(1) Pharmacist education on proper use of RDTs is critical to
ensure maximum utility [35], and (2) patient-specific assessments of drug resistance risk factors should be a focus.

appropriate oseltamivir use. However, optimizing RDTs relies
on communicating results and recommendations to prescribers.
Urgent Care Antimicrobial Stewardship Through Pharmacist-Led Culture
Follow-up

Syndrome-Specific Intervention: Candidemia

Candida species are the fourth leading reported cause of nosocomial BSIs, with hospital mortality rates approaching 40%
[38]. Shortening the time to appropriate therapy improves outcomes, including mortality [39, 40].
Rac and colleagues conducted a single-center, pre–post, quasi-experimental study evaluating a 1-time antifungal stewardship intervention consisting of antifungal susceptibility testing
paired with real-time culture alerts to the ASP pharmacist, who
then would review results and convey recommendations related
to antifungal therapy and ancillary care recommendations (ID
consult, remove lines, ophthalmology examination, repeated
blood cultures) to the primary team [19]. The ASP pharmacist
intervened 24 hours/day, with most activity occurring during
business hours (Monday–Friday from 6 am to 6 pm). The primary outcome was time to adequate antifungal therapy in the
business hours population, and secondary outcomes included
infection-related LOS, compliance with quality indicators, and
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Antimicrobial Stewardship in Nursing Homes

Interest in ASPs has been pivoting from a focus on hospitals
to other health care workers and settings, as evidenced by
TJC’s standard on ASP applicable to nursing homes [41], the
American Nurses Association/CDC White Paper on the role of
registered nurses in ASPs [42], and the National Quality Forum’s
Playbook on ASPs in postacute and long-term care [43].
Wilson and colleagues investigated nurses’ awareness of
their role as antimicrobial stewards in nursing homes through
pre– and post–online course surveys [20]. The course was free
of charge, consisted of six 30-minute interactive modules, and
provided 3.0 nursing contact hours. Assessing data from 71 registered nurses and 32 licensed practical nurses who completed
both pre and post surveys, a statistical improvement in knowledge scores was identified (75% to 86%; P < .0001). After taking
the course, respondents had heightened awareness that their
role influences whether residents receive antimicrobials (3.8 to
4.5 on a 5-point Likert scale; P < .001).
The limitations include a limited sample size with a high
attrition rate (103/200 nurses completed both surveys) and
the absence of an assessment on the long-term impact of the
intervention. Future research is warranted to further elucidate
effective mechanisms for educating nurses and engaging them
in ASP activities especially in non-acute care settings.
DISCUSSION

Regulation mandating ASPs is increasingly occurring across
the health care spectrum. Although there is exponential growth
in the number of ASP publications, most do not detail specific
interventions with subsequent effects on patient outcomes.
Documentation of both positive and negative outcomes with
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The CDC has published core elements for outpatient settings,
including urgent care facilities, where significant antimicrobial
prescribing occurs [37].
Dumkow and colleagues evaluated the feasibility of a pharmacist-led culture follow-up program at urgent care centers [18]. All
positive cultures from any source except blood, synovial, and cerebrospinal fluid were evaluated over the course of a year by either
an emergency department (ED) or ID pharmacist or pharmacy
practice resident located off-site under a collaborative practice
agreement (CPA). Of 1461 positive cultures reviewed, 320 (22%)
required intervention, with the most common being urine, sexually transmitted infections (STIs), and throat (Streptococcal species), respectively. The majority of the STI patients did not require
further treatment, only notification of results and counseling. Most
patients were contacted with 1 phone call and required an average
of 15 minutes for all interventions including documentation.
Of interest, the CPA in this study recommended no additional antibiotics prescribed if patients were asymptomatic at
the time of the call (60% of patients). The strengths of the study
include meaningful stewardship intervention, with minimal
increase in workload/time due to involvement of 3 different
pharmacists including a resident, all occurring in a community setting. CPAs may not be available in some areas, and the
authors did not delineate how many interventions were performed by the resident, which, depending on resources, could
limit generalizability. Additionally, further assessment of not
only interventions but outcomes is needed for comprehensive
evaluation of this service.

time to adequate and appropriate antifungal therapy in the total
population. Therapy was considered adequate if it had documented or expected in vitro susceptibility and appropriate if it
was the narrowest spectrum. There was no significant difference
in the primary end point between groups, but time to adequate
therapy and adequate therapy order in the total population were
both statistically shorter in the postintervention period. Time to
appropriate therapy was not different between groups in either
population. The intervention was associated with a statistically
significant increase in the number of ID and ophthalmology
consults and the number of patients switched to oral therapy.
The authors hypothesized that similarities in the primary
outcome were due to the large percentage of C. glabrata at this
institution, which may have resulted in more empiric echinocandin usage in both periods. The limitations include a single-center design, small study population, and heavy reliance on
the ID consult team to follow up on recommendations. Further
research at hospitals without specific ID-trained physicians or
consult teams would be beneficial.

Supplementary Data
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online. Consisting of data provided by the authors to benefit the reader, the
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specific interventions is imperative to aid ASPs in selecting
appropriate actions for their practice sites, especially for new or
resource-limited programs. With few antimicrobials with novel
mechanisms of action scheduled for FDA approval in the near
future, processes that optimize antimicrobials are vital [44].
Several major themes are evident within the chosen manuscripts. First, integration of RDTs into stewardship activities
improves outcomes [5, 8, 10, 11, 17]. Previous data describe a
lack of benefit of RDTs when not acted upon by the ASP [36].
Facilities must inventory resources to determine if these outcomes are reproducible within their patient population and
determine appropriate integration strategies.
Second, a growing literature supports shortening the duration of therapy for several diseases, as evidenced by our literature review, which found several articles shortening treatment
duration within the inpatient setting and at the time of discharge [14, 15]. Implementation of prescription reauthorization
with feedback on restricted antimicrobials decreased DOT and
overall LOS.
Third, data are emerging regarding ASPs in community
hospitals and health systems [5, 14, 18]. This is encouraging,
considering that these locations represent most facilities, and
many may not have significant resources to perform the CDC
core elements [4]. Further research will help determine the best
interventions for these patient populations.
As research focusing on specific, actionable stewardship
interventions continues to increase, clinicians should work to
stay familiar with key impactful interventions. Analyzing and
implementing these strategies will help promote ASP activities and ultimately attain what we are all after, better patient
outcomes.
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